查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870031

基因載體市場規模、佔有率和趨勢分析報告：按類型、遞送方式、治療領域、最終用途、地區和細分市場預測（2025-2033 年）

Gene Vector Market Size, Share & Trends Analysis Report By Type (Viral, Non-Viral), By Delivery Method, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

基因載體市場摘要

2024年全球基因載體市場規模估計為78.8億美元，預計2033年將達到426.1億美元。

預計2025年至2033年間，該市場將以20.92%的複合年成長率成長。主要成長要素包括遺傳疾病盛行率的上升、基因治療技術的進步以及為開發創新基因遞送系統而進行的研發活動的激增。隨著對標靶治療和個人化醫療需求的不斷成長，預計該市場將在幾個關鍵地區實現顯著成長。

病毒載體和非病毒載體技術的進展

病毒和非病毒載體技術的進步推動了全球基因載體產業的顯著成長。腺結合病毒（AAV）、慢病毒和逆轉錄病毒等病毒載體的持續創新，顯著提高了安全性、轉導效率和組織特異性靶向性。例如，新一代AAV具有更高的遞送效率和更低的免疫抗原性，使其成為治療遺傳性疾病和慢性疾病的理想選擇。

非病毒載體技術的進步進一步推動了市場發展。脂質奈米顆粒（LNP）、聚合物載體和電穿孔等物理遞送方法因其可擴展性、安全性更高以及能夠攜帶更大基因載荷等優勢，正日益成為病毒載體系統的替代方案。尤其是在新冠疫情期間，脂質奈米顆粒作為mRNA疫苗的載體，引起了全球的廣泛關注，進一步展現了其在癌症治療、罕見遺傳疾病和感染疾病方面的潛力。提高非病毒載體的遞送效率、降低細胞毒性和提高標靶精準度的研究與開發，仍是大規模商業化生產的重要方向。

對個人化醫療的需求日益成長

個人化醫療的日益普及是基因載體市場的主要成長要素。千篇一律的治療方法往往無法解決複雜罕見疾病的根本病因，因此，基於患者基因譜的個人化治療方法的需求日益成長。基因載體在開發這些個人化療法中發揮著至關重要的作用，它們能夠將治療基因直接遞送到目標細胞，從而從分子層面而非僅僅緩解症狀。隨著基因測序和生物標記發現技術的快速發展，醫療服務提供者越來越能夠根據患者的基因組成設計專屬治療方法，這也使得病毒載體和非病毒載體在這一轉型過程中扮演越來越重要的角色。

全球精準醫療舉措投入的不斷增加進一步推動了這一趨勢。各國政府、研究機構和製藥公司正致力於開發個人化治療模式，以改善患者療效、減少副作用並提高醫療成本效益。基因和細胞療法（通常基於載體）處於這一領域的前沿，越來越多的治療方法核准用於治療癌症、罕見遺傳疾病和遺傳性疾病。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 附隨市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素的影響分析
    • 市場限制因素的影響分析
  • 商業環境分析
    • PESTLE分析
    • 波特五力分析

第4章 基因載體市場：類型業務分析

  • 類型細分儀表板
  • 全球基因載體市場類型及波動分析
  • 全球基因載體市場規模及趨勢分析（按類型分類）（2021-2033年）
  • 病毒載體
  • 非病毒載體

5. 基因載體市場：遞送方式的業務分析

  • 配送方式細分儀表板
  • 全球基因載體市場遞送方式及變異分析
  • 全球基因載體市場規模及趨勢分析（依遞送方式分類，2021-2033 年）
  • 體內基因遞送
  • 體外基因遞送
  • 其他

6. 基因載體市場：治療領域業務分析

  • 治療領域細分儀表板
  • 全球基因載體市場治療領域變遷分析
  • 全球基因載體市場規模及趨勢分析（依治療領域分類，2021-2033 年）
  • 腫瘤學
  • 遺傳性疾病
  • 感染疾病
  • 心血管疾病
  • 神經系統疾病
  • 眼科疾病
  • 其他

7. 基因載體市場：終端用戶業務分析

  • 最終用戶細分儀表板
  • 全球基因載體市場最終用途及變異分析
  • 全球基因載體市場規模及趨勢分析（依最終用途分類，2021-2033 年）
  • 製藥和生物技術公司
  • 學術研究機構
  • 合約研究組織 (CRO) 和合約生產組織 (CMO)

8. 基因載體市場：區域估算和趨勢分析（按類型、遞送方法、治療領域和最終用途分類）

  • 區域儀錶板
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 2021-2033年北美基因載體市場
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲基因載體市場，2021-2033年
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區基因載體市場，2021-2033年
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 2021-2033年拉丁美洲基因載具市場
    • 巴西
    • 阿根廷
  • 中東和非洲
    • MEA 基因載體市場，2021-2033
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 公司分類
  • 策略規劃
  • 企業市場分析，2024年
  • 公司簡介
    • Charles River Laboratories
    • VGXI, Inc.
    • Danaher（Aldevron）
    • Kaneka Corp.
    • Eurofins Genomics
    • Cell and Gene Therapy Catapult
    • Catalent, Inc.
    • Lonza
    • Luminous BioSciences, LLC
    • Akron Biotech
Product Code: GVR-4-68040-757-2

Gene Vector Market Summary

The global gene vector market size was estimated at USD 7.88 billion in 2024 and is projected to reach USD 42.61 billion by 2033, growing at a CAGR of 20.92% from 2025 to 2033. The main growth drivers are the increasing prevalence of genetic disorders, advancements in gene therapy, and a boom in research and development efforts to create innovative gene delivery systems. The market is expected to grow significantly in several important global regions as the need for targeted therapies and personalized medicine keeps growing.

Advancements in Viral and Non-viral Vectors

The global gene vector industry is seeing significant growth due to advancements in viral and non-viral vector technology. Adeno-associated viruses (AAV), lentiviruses, and retroviruses are viral vectors whose safety profiles, transduction efficiency, and tissue-specific targeting have all been greatly enhanced by ongoing innovation. For example, next-generation AAVs are being developed with improved delivery efficiency and decreased immunogenicity, making them ideal for treating inherited and chronic diseases.

The market momentum is being strengthened by the advancements associated with non-viral vectors. Lipid nanoparticles (LNPs), carriers from polymers, and some form of physical delivery, such as electroporation, are increasingly used as alternatives to viral systems because they can be scaled up, have fewer safety concerns, and carry larger genetic payloads. LNPs, specifically, were brought to the forefront of global attention with the COVID-19 pandemic because mRNA vaccines utilized lipid nanoparticles as carriers, further demonstrating their therapeutic potential in the treatment of oncology, rare genetic diseases, and infectious diseases. The dedicated research and development to improve delivery efficiency, reduce cytotoxicity, and improve targeting accuracy of non-viral vectors are still attractive to large-scale commercial manufacturing.

Growing Demand for Personalized Medicine

The rising trend toward personalized medicine is a major growth driver for the gene vector market. Generic, one-size-fits-all treatments often fail to address the underlying cause of complex and rare diseases. This creates a demand for therapy designed for individual patients based on their genetic profile. Gene vectors will be integral to developing these personalized treatments that deliver therapeutic genes directly into targeted cells to help treat the molecular basis of disease, rather than simply addressing symptoms. As advancements in genomic sequencing and biomarker discovery accelerate, healthcare providers are better equipped to design therapies specific to a patient's genetic makeup, which, in turn, is increasing reliance on viral and non-viral vectors as essential tools in this transformation.

Growing investments in precision medicine initiatives across the globe further underscore this trend. Governments, research institutes, and pharmaceutical companies are focusing on personalized treatment models. They aim to improve patient outcomes, reduce side effects, and make healthcare more cost-effective. Gene and cell therapies, many of which are vector-based, are at the forefront of this movement, with increasing approvals of treatments for cancers, rare genetic disorders, and inherited conditions.

Global Gene Vector Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global gene vector market on the basis of type, delivery method, therapeutic area, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Viral Vectors
    • Adenoviral Vectors
    • Adeno-Associated Viral (AAV) Vectors
    • Lentiviral Vectors
    • Retroviral Vectors
    • Herpes Simplex Virus (HSV) Vectors
    • Others
  • Non-Viral Vectors
    • Plasmid DNA
    • Lipid Nanoparticles
    • Polymer-based Vectors
    • Others
  • Delivery Method Outlook (Revenue, USD Million, 2021 - 2033)
  • In-vivo Gene Delivery
  • Ex-vivo Gene Delivery
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Genetic Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Neurological Diseases
  • Ophthalmological Diseases
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • CROs & CMOs
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Type
    • 1.2.2. Delivery Method
    • 1.2.3. Therapeutic Area
    • 1.2.4. End use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Details
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Impact Analysis
      • 3.3.1.1. Advancements in viral and non-viral vectors
      • 3.3.1.2. Growing demand for personalized medicine
    • 3.3.2. Market Restraint Impact Analysis
      • 3.3.2.1. Regulatory and compliance challenges
  • 3.4. Business Environment Analysis
    • 3.4.1. PESTLE Analysis
    • 3.4.2. PORTER'S Five Forces Analysis

Chapter 4. Gene Vector Market: Type Business Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Global Gene Vector Market Type, Movement Analysis
  • 4.3. Global Gene Vector Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Viral Vectors
    • 4.4.1. Global viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Adenoviral Vectors
      • 4.4.2.1. Global adenoviral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Adeno-Associated Viral (AAV) Vectors
      • 4.4.3.1. Global adeno-associated viral (AAV) Vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Lentiviral Vectors
      • 4.4.4.1. Global lentiviral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.5. Retroviral Vectors
      • 4.4.5.1. Global retroviral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.6. Herpes Simplex Virus (HSV) Vectors
      • 4.4.6.1. Global herpes simplex virus (HSV) Vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.7. Others
      • 4.4.7.1. Global other viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Non-Viral Vectors
    • 4.5.1. Global non-viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.2. Plasmid DNA
      • 4.5.2.1. Global plasmid DNA market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.3. Lipid Nanoparticles
      • 4.5.3.1. Global lipid nanoparticles market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.4. Polymer-based Vectors
      • 4.5.4.1. Global polymer-based vectors market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.5.5. Others
      • 4.5.5.1. Global other non-viral vectors market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Gene Vector Market: Delivery Method Business Analysis

  • 5.1. Delivery Method Segment Dashboard
  • 5.2. Global Gene Vector Market Delivery Method, Movement Analysis
  • 5.3. Global Gene Vector Market Size & Trend Analysis, by Delivery Method, 2021 to 2033 (USD Million)
  • 5.4. In-vivo Gene Delivery
    • 5.4.1. Global in-vivo gene delivery market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Ex-vivo Gene Delivery
    • 5.5.1. Global ex-vivo gene delivery market estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Gene Vector Market: Therapeutic Area Business Analysis

  • 6.1. Therapeutic Area Segment Dashboard
  • 6.2. Global Gene Vector Market Therapeutic Area, Movement Analysis
  • 6.3. Global Gene Vector Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Global oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Genetic Diseases
    • 6.5.1. Global genetic disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Infectious Diseases
    • 6.6.1. Global infectious disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7. Cardiovascular Diseases
    • 6.7.1. Global cardiovascular disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.8. Neurological Diseases
    • 6.8.1. Global neurological disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.9. Ophthalmological Diseases
    • 6.9.1. Global ophthalmological disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.10. Others
    • 6.10.1. Global others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Gene Vector Market: End Use Business Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. Global Gene Vector Market End use, Movement Analysis
  • 7.3. Global Gene Vector Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Global pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Academic & Research Institutes
    • 7.5.1. Global academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. CROs & CMOs
    • 7.6.1. Global CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Gene Vector Market: Regional Estimates and Trend Analysis, by Type, Delivery Method, Therapeutic Area, & End Use

  • 8.1. Regional Dashboard
  • 8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 8.3. North America
    • 8.3.1. North America gene vector market, 2021 - 2033 (USD Million)
    • 8.3.2. U.S.
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. U.S. gene vector market, 2021 - 2033 (USD Million)
    • 8.3.3. Canada
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Canada gene vector market, 2021 - 2033 (USD Million)
    • 8.3.4. Mexico
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Mexico gene vector market, 2021 - 2033 (USD Million)
  • 8.4. Europe
    • 8.4.1. Europe gene vector market, 2021 - 2033 (USD Million)
    • 8.4.2. UK
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. UK gene vector market, 2021 - 2033 (USD Million)
    • 8.4.3. Germany
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Germany gene vector market, 2021 - 2033 (USD Million)
    • 8.4.4. France
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. France gene vector market, 2021 - 2033 (USD Million)
    • 8.4.5. Italy
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Italy gene vector market, 2021 - 2033 (USD Million)
    • 8.4.6. Spain
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Spain gene vector market, 2021 - 2033 (USD Million)
    • 8.4.7. Denmark
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Denmark gene vector market, 2021 - 2033 (USD Million)
    • 8.4.8. Sweden
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Competitive Scenario
      • 8.4.8.3. Regulatory Framework
      • 8.4.8.4. Sweden gene vector market, 2021 - 2033 (USD Million)
    • 8.4.9. Norway
      • 8.4.9.1. Key Country Dynamics
      • 8.4.9.2. Competitive Scenario
      • 8.4.9.3. Regulatory Framework
      • 8.4.9.4. Norway gene vector market, 2021 - 2033 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Asia Pacific gene vector market, 2021 - 2033 (USD Million)
    • 8.5.2. Japan
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Japan gene vector market, 2021 - 2033 (USD Million)
    • 8.5.3. China
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. China gene vector market, 2021 - 2033 (USD Million)
    • 8.5.4. India
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. India gene vector market, 2021 - 2033 (USD Million)
    • 8.5.5. Australia
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Australia gene vector market, 2021 - 2033 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Thailand gene vector market, 2021 - 2033 (USD Million)
    • 8.5.7. South Korea
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. South Korea gene vector market, 2021 - 2033 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Latin America gene vector market, 2021 - 2033 (USD Million)
    • 8.6.2. Brazil
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Brazil gene vector market, 2021 - 2033 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Argentina gene vector market, 2021 - 2033 (USD Million)
  • 8.7. MEA
    • 8.7.1. MEA gene vector market, 2021 - 2033 (USD Million)
    • 8.7.2. South Africa
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. South Africa gene vector market, 2021 - 2033 (USD Million)
    • 8.7.3. Saudi Arabia
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Saudi Arabia gene vector market, 2021 - 2033 (USD Million)
    • 8.7.4. UAE
      • 8.7.4.1. Key Country Dynamics
      • 8.7.4.2. Competitive Scenario
      • 8.7.4.3. Regulatory Framework
      • 8.7.4.4. UAE gene vector market, 2021 - 2033 (USD Million)
    • 8.7.5. Kuwait
      • 8.7.5.1. Key Country Dynamics
      • 8.7.5.2. Competitive Scenario
      • 8.7.5.3. Regulatory Framework
      • 8.7.5.4. Kuwait gene vector market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. Charles River Laboratories
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. VGXI, Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Danaher (Aldevron)
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Kaneka Corp.
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Eurofins Genomics
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Cell and Gene Therapy Catapult
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Catalent, Inc.
      • 9.4.7.1. Overview
      • 9.4.7.2. Product Benchmarking
      • 9.4.7.3. Strategic Initiatives
    • 9.4.8. Lonza
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Luminous BioSciences, LLC
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Akron Biotech
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Global Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 4. Global Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 5. Global Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 6. Global Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 7. Global Gene Vector Market, by Region, 2021 - 2033 (USD Million)
  • Table 8. North America Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 9. North America Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 10. North America Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 11. North America Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 12. North America Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 13. U.S. Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 14. U.S. Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 15. U.S. Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 16. U.S. Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 17. Canada Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 18. Canada Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 19. Canada Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 20. Canada Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 21. Mexico Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 22. Mexico Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 23. Mexico Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 24. Mexico Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 25. Europe Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 26. Europe Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 27. Europe Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 28. Europe Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 29. Europe Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 30. Germany Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 31. Germany Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 32. Germany Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 33. Germany Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 34. UK Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 35. UK Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 36. UK Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 37. UK Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 38. France Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 39. France Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 40. France Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 41. France Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 42. Italy Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 43. Italy Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 44. Italy Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 45. Italy Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 46. Spain Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 47. Spain Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 48. Spain Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 49. Spain Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 50. Denmark Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 51. Denmark Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 52. Denmark Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 53. Denmark Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 54. Norway Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 55. Norway Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 56. Norway Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 57. Norway Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 58. Sweden Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 59. Sweden Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 60. Sweden Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 61. Sweden Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 62. Asia Pacific Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 63. Asia Pacific Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 64. Asia Pacific Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 65. Asia Pacific Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 66. Asia Pacific Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 67. China Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 68. China Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 69. China Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 70. China Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 71. Japan Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 72. Japan Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 73. Japan Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 74. Japan Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 75. India Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 76. India Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 77. India Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 78. India Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 79. South Korea Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 80. South Korea Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 81. South Korea Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 82. South Korea Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 83. Australia Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 84. Australia Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 85. Australia Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 86. Australia Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 87. Thailand Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 88. Thailand Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 89. Thailand Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 90. Thailand Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 91. Latin America Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 92. Latin America Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 93. Latin America Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 94. Latin America Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 95. Latin America Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 96. Brazil Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 97. Brazil Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 98. Brazil Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 99. Brazil Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 100. Argentina Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 101. Argentina Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 102. Argentina Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 103. Argentina Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 104. Middle East and Africa Gene Vector Market, by Country, 2021 - 2033 (USD Million)
  • Table 105. Middle East and Africa Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 106. Middle East and Africa Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 107. Middle East and Africa Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 108. Middle East and Africa Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 109. South Africa Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 110. South Africa Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 111. South Africa Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 112. South Africa Gene Vector Market, by End use, 2021 - 2033 (USD Million)
  • Table 113. Saudi Arabia Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 114. Saudi Arabia Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 115. Saudi Arabia Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 116. Saudi Arabia Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 117. UAE Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 118. UAE Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 119. UAE Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 120. UAE Gene Vector Market, by End Use, 2021 - 2033 (USD Million)
  • Table 121. Kuwait Gene Vector Market, by Type, 2021 - 2033 (USD Million)
  • Table 122. Kuwait Gene Vector Market, by Delivery Method, 2021 - 2033 (USD Million)
  • Table 123. Kuwait Gene Vector Market, by Therapeutic Area, 2021 - 2033 (USD Million)
  • Table 124. Kuwait Gene Vector Market, by End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Gene vector market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validation & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Market trends & outlook
  • Fig. 16 PESTEL analysis
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 Gene vector market: Type outlook key takeaways
  • Fig. 19 Gene vector market: Type movement analysis
  • Fig. 20 Viral vectors market, 2021 - 2033 (USD Million)
  • Fig. 21 Non-viral vectors market, 2021 - 2033 (USD Million)
  • Fig. 22 Gene vector market: Delivery Method outlook key takeaways
  • Fig. 23 Gene vector market: Delivery Method movement analysis
  • Fig. 24 In-vivo gene delivery, 2021 - 2033 (USD Million)
  • Fig. 25 Ex-vivo gene delivery, 2021 - 2033 (USD Million)
  • Fig. 26 Others, 2021 - 2033 (USD Million)
  • Fig. 27 Gene vector market: Therapeutic Area outlook key takeaways
  • Fig. 28 Gene vector market: Therapeutic Area movement analysis
  • Fig. 29 Oncology, 2021 - 2033 (USD Million)
  • Fig. 30 Genetic Diseases, 2021 - 2033 (USD Million)
  • Fig. 31 Infectious Diseases, 2021 - 2033 (USD Million)
  • Fig. 32 Cardiovascular Diseases, 2021 - 2033 (USD Million)
  • Fig. 33 Neurological Diseases, 2021 - 2033 (USD Million)
  • Fig. 34 Ophthalmological Diseases, 2021 - 2033 (USD Million)
  • Fig. 35 Others, 2021 - 2033 (USD Million)
  • Fig. 36 Gene vector market: End use outlook key takeaways
  • Fig. 37 Gene vector market: End use movement analysis
  • Fig. 38 Pharmaceutical & biotechnology companies market, 2021 - 2033 (USD Million)
  • Fig. 39 Academic & research institutions market, 2021 - 2033 (USD Million)
  • Fig. 40 CROs & CMOs market, 2021 - 2033 (USD Million)
  • Fig. 41 Regional marketplace outlook, 2024 & 2033 (USD Million)
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 U.S. gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Canada gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Mexico gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 50 Europe gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Germany gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 53 Key country dynamics
  • Fig. 54 UK gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 France gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Italy gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 Spain gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Denmark gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Sweden gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Norway gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 67 Asia Pacific gene vector market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Japan gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 China gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 South Korea gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Australia gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Thailand gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Latin America gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Brazil gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Argentina gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 MEA gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Key country dynamics
  • Fig. 87 South Africa gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Saudi Arabia gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 UAE gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Kuwait gene vector market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Market position analysis
  • Fig. 95 Market participant categorization
  • Fig. 96 Strategic framework